Accueil   Diary - News   All events Bio Trinity 2020

Bio Trinity 2020

 
 

BioTrinity is a long-running and highly regarded two day life sciences conference that takes place in Central London from 28-29 April.  BioTrinity focuses on partnering, investment and collaboration and aims to inspire growth and create opportunities for all who attend.  The core delegate mix includes early-stage and emerging biotech, medtech and digital health companies, big pharma executives and life sciences investors. 

 
 

Why attend BioTrinity?


As a leading international biopartnering and investment conference, people choose to attend BioTrinity for a range of reasons, including:
 

  • To seek collaboration partners
  • To discover new investment and in-licensing opportunities
  • To learn about the latest industry trends
  • To keep updated on new innovation and technology
  • To network and build new relationships
  • To raise their company profile to a targeted and engaged audience

 

Conference Highlights
 

  • Two days of pre-scheduled private 1:1 partnering meetings
  • Packed agenda of panel discussions, keynotes, fireside chats and case studies
  • BioLaunchPad showcase featuring up to 70 back to back 5-minute company presentations from innovative R&D companies
  • New for 2020 – an offsite Delegate Dinner on Tuesday 28 April
  • Plenty of informal networking opportunities and meeting spaces available for all delegates

 

Open recruitment, find out more

See all events

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree